Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Dec;88(12):1174-1179.
doi: 10.1007/s12098-021-03659-y. Epub 2021 Feb 24.

Duration of Caffeine for Apnea of Prematurity-A Randomized Controlled Trial

Raj Prakash  1 , Femitha Pournami  2 , Jyothi Prabhakar  1 , Anand Nandakumar  1 , P M C Nair  1 , Naveen Jain  1
Affiliations
Randomized Controlled Trial

Duration of Caffeine for Apnea of Prematurity-A Randomized Controlled Trial

Raj Prakash et al. Indian J Pediatr. 2021 Dec.

Abstract

Objectives: There is sufficient evidence to support use of caffeine therapy for apnea of prematurity, but practices vary widely when it comes to discontinuing therapy. This study was planned to compare 'recurrence of apnea of prematurity' (RAP); when 2 protocols were used to stop caffeine therapy.

Methods: Neonates delivered at 26-32 wk gestation on caffeine therapy for apnea of prematurity were randomized into 2 groups: Group 1-caffeine stopped at 7 d apnea-free period, and Group 2-continued for a prefixed period till at least 34 wk postmenstrual age (PMA). Proportion of infants in each group with RAP were analyzed.

Results: Each group consisted of 60 infants. Proportion of infants in each group with RAP, were not different (15% vs 13%); odds ratio (OR) 0.87; 95% confidence interval (CI) (0.31-2.43). Caffeine could be stopped earlier (33 vs 34 wk PMA); and cumulative duration of therapy was lesser (19.5 vs 33 d) when stopped at 7 d apnea-free period. Other studied outcomes were similar between the two groups.

Conclusions: Mandatorily continuing caffeine therapy up to 34 wk PMA in select preterm groups does not seem to decrease risk of recurrence of apnea. Larger trials that specifically study extremely preterm infants are required to make robust recommendations on when to stop therapy.

Clinical trials registry of india no: CTRI/2016/12/007559. http://ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=14195&EncHid=&modid=&compid=%27,%2714195det%27.

Keywords: Apnea of prematurity; Caffeine; Duration of therapy.

PubMed Disclaimer

Comment in

References

    1. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112–21. - DOI
    1. Hsieh EM, Hornik CP, Clark RH, Laughon MM, Benjamin DK, Smith PB; On behalf of the Best Pharmaceuticals for Children Act- Pediatrics trials network. Medication use in the neonatal intensive care unit. Am J Perinatol. 2014;31(9):811–22.
    1. Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007;357(19):1893–902. - DOI
    1. Lodha A, Seshia M, McMillan DD, et al. Association of early caffeine administration and neonatal outcomes in very preterm neonates. JAMA Pediatr. 2015;169:33–8. - DOI
    1. Kattwinkel J, Nattie C, Robinson M. Margin of safety for discharge after apnea in preterm infants. Pediatrics. 1997;100:795–801. - DOI

Publication types

LinkOut - more resources